CoronaryAtlas logo
CoronaryAtlas
citrullinated histone H3
Pathway / Plaque inflammation

citrullinated histone H3

H3C1protein

NETosis product serving as specific marker of neutrophil extracellular trap burden and pathogenic plaque inflammation.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleCanonical NET marker produced by PAD4-mediated histone modification.
Also acts inPlatelet activation
Druggability
DruggableNo
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableNo
EnsemblENSG00000275714

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
71
C — confounder / Type-II
63
A — assay feasibility
68
E — evidence strength
28
T1DI (composite)
10
Specificity differential (R−C)+7.5
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(2)